These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34370737)

  • 1. An open science pathway for drug marketing authorization-Registered drug approval.
    Naudet F; Siebert M; Boussageon R; Cristea IA; Turner EH
    PLoS Med; 2021 Aug; 18(8):e1003726. PubMed ID: 34370737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
    Seitz R; Enzmann H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory pathways in the European Union.
    Kohler M
    MAbs; 2011; 3(3):241-2. PubMed ID: 21487236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EU marketing authorization review of orphan and non-orphan drugs does not differ.
    Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
    Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
    Nettesheim M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
    Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 11. [Marketing of pediatric drugs].
    Pabst JY
    Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
    Enzmann H; Schneider C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 15. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractured European market undermines biosimilar launches.
    Moran N
    Nat Biotechnol; 2008 Jan; 26(1):5-6. PubMed ID: 18183000
    [No Abstract]   [Full Text] [Related]  

  • 17. [Editorial Letter. Drug approval].
    Borvendég J
    Neuropsychopharmacol Hung; 2011 Jun; 13(2):54-5. PubMed ID: 21919287
    [No Abstract]   [Full Text] [Related]  

  • 18. First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy.
    VandenDriessche T; Pipe SW; Pierce GF; Kaczmarek R
    Mol Ther; 2022 Nov; 30(11):3335-3336. PubMed ID: 36261044
    [No Abstract]   [Full Text] [Related]  

  • 19. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.